UK biotech Epsilogen has acquired US-based antibody developer TigaTx in a deal that collates work from the two companies’ ...

The global CD Antigen Cancer Therapy Market is valued at USD 27.5 Billion in 2024 and is projected to reach a value of USD 54 ...

produced by dying cells can stimulate an immune response that can elicit the specific recognition of antigens expressed by dying cells (for example, tumour antigens). The nature of the immune ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Kanazawa University and colleagues have developed a promising new approach to cancer treatment. By using tiny, naturally ...

Epsilogen’s earlier stage pipeline also features a number of other IgE antibody candidates targeting a variety of tumour antigens. Epsilogen is the world’s leading pan-isotype antibody ...

Assessing prostate-specific antigen levels for 3 months after radical prostatectomy may help minimize overtreatment, ...

Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...